New drug cocktail aims to tame deadly transplant complication
NCT ID NCT07509749
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug ruxolitinib to standard steroid treatment can better control severe acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. The study will enroll 54 people who develop severe GVHD within 100 days of their transplant. The main goal is to see if more patients achieve a complete or partial response by day 28 of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib and methylprednisolone
- What this could lead to
- If successful, this could offer a more effective first-line treatment for severe acute GVHD, improving response rates and survival after stem cell transplants.
- What could go wrong
- This is a small phase 2 trial with only 54 participants, so results may not apply broadly. The combination therapy also carries risks like infection and side effects from steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, the Fifth Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bedtime kit for the hospital: can ear plugs and a lightbox help young transplant patients sleep?
- New drug shows promise in controlling transplant complications
- Placenta cell therapy shows promise for tough transplant complication
- Blood test may spot deadly transplant complication earlier
- Simple blood test may predict deadly transplant complication
- New hope for kids with sickle cell: stem cell transplant from mismatched blood type donors